OBJECTIVE: Type 1 diabetes is associated with increased microvascular complications and inflammation. The monocyte-macrophage is a pivotal cell in atherogenesis. There are scanty data on noninvasive measures of microvascular abnormalities and inflammation in type 1 diabetic subjects with microvascular complications. Thus, we examined systemic and cellular biomarkers of inflammation in type 1 diabetic patients with microvascular complications (T1DM-MV patients) and type 1 diabetic patients without microvascular complications (T1DM patients) compared with matched control subjects and determined the microcirculatory abnormalities in the T1DM and T1DM-MV patients using computer-assisted intravital microscopy (CAIM). RESEARCH DESIGN AND METHODS: Fasting blood, 24-h urine, and CAIM measurements were obtained from the T1DM and T1DM-MV patients and matched control subjects. C-reactive protein, E-selectin, nitrotyrosine, monocyte superoxide, and cytokines were elevated in the T1DM and T1DM-MV patients compared with control subjects (P < 0.01). RESULTS: Severity index, as assessed by CAIM, was significantly increased in the T1DM and T1DM-MV patients compared with the control subjects (P < 0.001). There was a significant increase in C-reactive protein, nitrotyrosine, vascular cell adhesion molecule and monocyte superoxide anion release, and interleukin-1 release in T1DM-MV compared with T1DM patients (P < 0.05). T1DM-MV patients had significantly increased CAIM severity index and microalbumin-to-creatinine ratio compared with T1DM patients (P < 0.05). Furthermore, pp38MAPK, pp65, and pERK activity were significantly increased in monocytes from the T1DM and T1DM-MV patients compared with those from the controls subjects, and pp38MAPK and pp65 activity were significantly increased in the T1DM-MV compared with the T1DM patients (P < 0.01). CONCLUSIONS: T1DM-MV patients have increased inflammation compared with T1DM patients. CAIM provides an effective biomarker of microvascular complications, since it is significantly elevated in T1DM-MV compared with T1DM patients and can be monitored following therapies targeted at improving inflammation and/or microvascular complications of type 1 diabetes.
OBJECTIVE: Type 1 diabetes is associated with increased microvascular complications and inflammation. The monocyte-macrophage is a pivotal cell in atherogenesis. There are scanty data on noninvasive measures of microvascular abnormalities and inflammation in type 1 diabetic subjects with microvascular complications. Thus, we examined systemic and cellular biomarkers of inflammation in type 1 diabeticpatients with microvascular complications (T1DM-MV patients) and type 1 diabeticpatients without microvascular complications (T1DM patients) compared with matched control subjects and determined the microcirculatory abnormalities in the T1DM and T1DM-MV patients using computer-assisted intravital microscopy (CAIM). RESEARCH DESIGN AND METHODS: Fasting blood, 24-h urine, and CAIM measurements were obtained from the T1DM and T1DM-MV patients and matched control subjects. C-reactive protein, E-selectin, nitrotyrosine, monocyte superoxide, and cytokines were elevated in the T1DM and T1DM-MV patients compared with control subjects (P < 0.01). RESULTS: Severity index, as assessed by CAIM, was significantly increased in the T1DM and T1DM-MV patients compared with the control subjects (P < 0.001). There was a significant increase in C-reactive protein, nitrotyrosine, vascular cell adhesion molecule and monocyte superoxide anion release, and interleukin-1 release in T1DM-MV compared with T1DM patients (P < 0.05). T1DM-MV patients had significantly increased CAIM severity index and microalbumin-to-creatinine ratio compared with T1DM patients (P < 0.05). Furthermore, pp38MAPK, pp65, and pERK activity were significantly increased in monocytes from the T1DM and T1DM-MV patients compared with those from the controls subjects, and pp38MAPK and pp65 activity were significantly increased in the T1DM-MV compared with the T1DM patients (P < 0.01). CONCLUSIONS: T1DM-MV patients have increased inflammation compared with T1DM patients. CAIM provides an effective biomarker of microvascular complications, since it is significantly elevated in T1DM-MV compared with T1DM patients and can be monitored following therapies targeted at improving inflammation and/or microvascular complications of type 1 diabetes.
Authors: Peter Libby; David M Nathan; Kristin Abraham; John D Brunzell; Judith E Fradkin; Steven M Haffner; Willa Hsueh; Marian Rewers; B Tibor Roberts; Peter J Savage; Sonia Skarlatos; Momtaz Wassef; Cristina Rabadan-Diehl Journal: Circulation Date: 2005-06-28 Impact factor: 29.690
Authors: C G Schalkwijk; D C Poland; W van Dijk; A Kok; J J Emeis; A M Dräger; A Doni; V W van Hinsbergh; C D Stehouwer Journal: Diabetologia Date: 1999-03 Impact factor: 10.122
Authors: S J Hwang; C M Ballantyne; A R Sharrett; L C Smith; C E Davis; A M Gotto; E Boerwinkle Journal: Circulation Date: 1997-12-16 Impact factor: 29.690
Authors: M A Hofmann; S Schiekofer; B Isermann; M Kanitz; M Henkels; M Joswig; A Treusch; M Morcos; T Weiss; V Borcea; A K Abdel Khalek; J Amiral; H Tritschler; E Ritz; P Wahl; R Ziegler; A Bierhaus; P P Nawroth Journal: Diabetologia Date: 1999-02 Impact factor: 10.122
Authors: Miranda T Schram; Nish Chaturvedi; Casper Schalkwijk; Francesco Giorgino; Pertti Ebeling; John H Fuller; Coen D Stehouwer Journal: Diabetes Care Date: 2003-07 Impact factor: 19.112
Authors: Liang Wang; Jin Yuan; Hong Jiang; Wentao Yan; Hector R Cintrón-Colón; Victor L Perez; Delia C DeBuc; William J Feuer; Jianhua Wang Journal: Eye Contact Lens Date: 2016-03 Impact factor: 2.018
Authors: Anthony T W Cheung; Joshua W Miller; Sarah M Craig; Patricia L To; Xin Lin; Sandra L Samarron; Peter C Y Chen; Theodore Zwerdling; Ted Wun; Chin-Shang Li; Ralph Green Journal: Am J Hematol Date: 2010-11 Impact factor: 10.047
Authors: Wenbo Zhi; Ashok Sharma; Sharad Purohit; Eric Miller; Bruce Bode; Stephen W Anderson; John Chip Reed; R Dennis Steed; Leigh Steed; Diane Hopkins; Jin-Xiong She Journal: Mol Cell Proteomics Date: 2011-09-06 Impact factor: 5.911
Authors: Maziyar M Khansari; William O'Neill; Richard Penn; Felix Chau; Norman P Blair; Mahnaz Shahidi Journal: Biomed Opt Express Date: 2016-06-16 Impact factor: 3.732
Authors: Camilla Noelle Rathcke; Frederik Persson; Lise Tarnow; Peter Rossing; Henrik Vestergaard Journal: Diabetes Care Date: 2008-10-28 Impact factor: 19.112